1. Introduction {#sec1}
===============

Cancer is one of the leading causes of death across the world, with an estimate of over 20 million new cancer cases that will occur per year as early as 2025 \[[@B1]\]. Although great efforts have been devoted to cancer treatment, cancer still poses a huge threat to human health. Carcinogenesis is rather complex, and mounting evidence suggests that reactive oxygen species- (ROS-) related oxidative damage is involved in this process \[[@B2]--[@B4]\].

Among the endogenous antioxidants, manganese superoxide dismutase (MnSOD) is one of the critical enzymes which defends against ROS in the mitochondria. The *MnSOD* gene, located on chromosome 6q25.3, is composed of four introns and five extrons. Currently, several single-nucleotide polymorphisms (SNPs) in the *MnSOD* gene have been reported, of which the most extensively studied one is Val16Ala. Since this residue is 9 amino acids upstream of the cleavage site, it has also been called Val9Ala (rs4880) polymorphism \[[@B5]\]. A previous study has shown that Ala-*MnSOD* allowed more efficient *MnSOD* localized to the mitochondria than the Val-variant form \[[@B6]\]. In view of this, it is speculated that the Val form of *MnSOD* may be associated with higher levels of ROS and increased susceptibility to cancer.

Several studies have found the associations between the Val form of the *MnSOD* gene and increased cancer risk \[[@B7]--[@B9]\], but a majority of studies showed the Ala form to be associated with higher cancer risk, such as breast cancer \[[@B10], [@B11]\], esophageal cancer \[[@B12]\], colorectal cancer \[[@B13]\], and cervical cancer \[[@B14]\], and some other studies find no significant association between this polymorphism and cancer risk \[[@B15]--[@B18]\]. To draw a more comprehensive estimation of this possible association, we conducted the present meta-analysis to evaluate the relevance of this variant with susceptibility of cancer.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We systematically searched the PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases for all related publications using the following keywords: "*MnSOD* or manganese superoxide dismutase," "polymorphism or variant or variation," and "cancer or carcinoma or tumor or neoplasm" (the last search was updated on February 22, 2018). Additional relevant studies were searched manually from the references or review articles about this topic. If studies had overlapped data, only the one with the most participants was included in this analysis.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria were as follows: (1) case-control studies, (2) studies assessing the association between *MnSOD* Val16Ala polymorphism and cancer risk, (3) and provision of detailed data about genotype and allele distribution of the studied polymorphism. Studies were excluded if any of the following aspects existed: (1) duplicate publications, (2) review articles or meta-analyses, (3) not a case-control study, and (4) genotype frequencies in the control departure from Hardy-Weinberg equilibrium (HWE).

2.3. Data Extraction {#sec2.3}
--------------------

Two authors (Ping Wang and Yanfeng Zhu) independently extracted the data from included studies according to the criteria mentioned above. Disagreement was resolved by discussion until a consensus was reached. The following information was collected from each study: first author\'s surname, year of publication, country of origin, ethnicity, cancer type, control source (hospital-based or population-based), genotyping methods, and numbers of cases and controls with the Val/Val, Val/Ala, and Ala/Ala genotypes.

2.4. Quality Assessment {#sec2.4}
-----------------------

The quality of each included study was assessed independently by two authors using the criteria from a previous study \[[@B19]\]. Quality scores were rated from 0 to 15, and the studies were classified as high-quality studies (scores \> 9) and low-quality studies (scores ≤ 9).

2.5. Statistical Analysis {#sec2.5}
-------------------------

The strength of association between the *MnSOD* Val16Ala polymorphism and cancer risk was assessed by calculating the odd ratios (ORs) with the corresponding 95% confidence intervals (CIs). The pooled ORs of five comparison models were calculated: homozygous model (Ala/Ala versus Val/Val), heterozygous model (Val/Ala versus Val/Val), recessive model \[Ala/Ala versus (Val/Val + Val/Ala)\], dominant model \[(Ala/Ala + Val/Ala) versus Val/Val\], and an allele comparison (Ala versus Val). We used the chi-square-based *Q* test to check the between-study heterogeneity, and the fixed-effects model (the Mantel-Haenszel method) \[[@B20]\] was used when no significant heterogeneity was found (*P* \> 0.1). Otherwise, the random-effects model (the Dersimonian and Laird method) \[[@B21]\] was applied. The stratification analysis was performed by cancer type (cancer types with less than three studies would be merged into the "others" group), ethnicity (Asians, Caucasians, Africans, or mixed which contained more than one ethnic group), control source (hospital-based studies and population-based studies), and quality scores (≤9 and \>9). Publication bias was examined using Begg\'s funnel plot \[[@B22]\] and Egger\'s linear regression test \[[@B23]\]. Sensitivity analysis was carried out to assess the results stability by excluding one study each time and revaluating the pooled ORs and 95% CIs.

The false-positive report probability (FPRP) was calculated for all the significant findings in the present study. We set 0.2 as a FPRP threshold and assign a prior probability of 0.1 to detect an OR of 0.67/1.50 (protective/risk effects) for an association with the genotypes under investigation \[[@B24], [@B25]\]. FPRP values less than 0.2 were considered as noteworthy associations. All the statistical tests were performed with STATA software (version 12.0; Stata Corporation, College Station, TX). Two-sided *P* values \<0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, a total of 348 articles were identified from PubMed, Embase, CNKI, and Wanfang databases, and 34 more articles were identified by reading the references of retrieved publications. After reading the titles and abstracts, 266 articles were excluded, leaving 116 articles for further assessment. Among them, six were excluded as case-only studies \[[@B26]--[@B31]\], five \[[@B32]--[@B36]\] were covered by other included publications \[[@B7], [@B37], [@B38]\], three were without detailed data for further analysis \[[@B39]--[@B41]\], and 18 deviated from HWE \[[@B42]--[@B59]\]. Finally, a total of 84 case-control publications \[[@B7]--[@B18], [@B37], [@B38], [@B60]--[@B129]\] were included in this meta-analysis. Of the 84 publications, three publications \[[@B37], [@B69], [@B82]\] with two ethnic groups were considered as two independent studies and one publication \[[@B119]\] with two cancer types were also considered as two independent studies.

For the two studies in the publication \[[@B119]\] with the same control group, the number of control was only calculated once in the total number. Overall, 88 studies with 33,098 cases and 37,831 controls were included in this meta-analysis. Of the 88 studies, 24 studies focused on breast cancer \[[@B9]--[@B11], [@B16], [@B38], [@B60], [@B61], [@B68], [@B69], [@B71], [@B72], [@B77], [@B88], [@B93], [@B96], [@B97], [@B100], [@B105], [@B109], [@B114], [@B119], [@B122], [@B127]\]; 17 on prostate cancer \[[@B37], [@B66], [@B74], [@B79], [@B82], [@B85], [@B86], [@B89], [@B95], [@B106], [@B111], [@B113], [@B120], [@B125], [@B128]\]; six for each of the following cancer types, such as lung cancer \[[@B7], [@B17], [@B18], [@B65], [@B92], [@B118]\], bladder cancer \[[@B8], [@B15], [@B67], [@B75], [@B112], [@B117]\], and pancreatic cancer \[[@B64], [@B91], [@B102], [@B107], [@B108], [@B121]\]; five on colorectal cancer \[[@B13], [@B63], [@B73], [@B94], [@B101]\]; three for each of the following cancer types, such as ovarian cancer \[[@B70], [@B81], [@B87]\], hepatocellular carcinoma \[[@B98], [@B99], [@B129]\], and non-Hodgkin\'s lymphoma \[[@B76], [@B78], [@B110]\]; and the other with fewer than three studies for each cancer type. Of all the studies, 56 studies were performed on Caucasians, 18 studies on Asians, and seven studies on Africans and mixed ethnicity, respectively. When classified by source of control, 48 were population-based and 40 were hospital-based. In addition, according to the quality score, 49 studies were considered as high-quality and 39 studies were considered as low-quality. The characteristics of the included studies are shown in [Table 1](#tab1){ref-type="table"}.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

The overall results suggested there was a significant association between *MnSOD* Val16Ala polymorphism and cancer risk (homozygous: OR = 1.09, 95% CI = 1.00--1.19, *P* \< 0.001; heterozygous: OR = 1.07, 95% CI = 1.02--1.12, *P* = 0.001; dominant: OR = 1.08, 95% CI = 1.02--1.14, *P* \< 0.001; and allele comparison: OR = 1.06, 95% CI = 1.02--1.11, *P* \< 0.001) ([Table 2](#tab2){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}). In the subgroup analysis, a statistically significant association was found for prostate cancer (heterozygous: OR = 1.14, 95% CI = 1.05--1.24, *P* = 0.765; dominant: OR = 1.14, 95% CI = 1.05--1.23, *P* = 0.552; and allele comparison: OR = 1.07, 95% CI = 1.00--1.15, *P* = 0.106), Asians (homozygous: OR = 1.82, 95% CI = 1.15--2.88, *P* = 0.020, and recessive: OR = 1.76, 95% CI = 1.16--2.68, *P* = 0.065), Caucasians (heterozygous: OR = 1.08, 95% CI = 1.03--1.13, *P* = 0.208; dominant: OR = 1.08, 95% CI = 1.02--1.14, *P* = 0.011; and allele comparison: OR = 1.04, 95% CI = 1.00--1.09, *P* \< 0.001), population-based studies (homozygous: OR = 1.10, 95% CI = 1.01--1.19, *P* \< 0.001; heterozygous: OR = 1.07, 95% CI = 1.02--1.12, *P* = 0.263; dominant: OR = 1.07, 95% CI = 1.02--1.13, *P* = 0.071; and allele comparison: OR = 1.04, 95% CI = 1.00--1.08, *P* = 0.006), hospital-based studies (recessive: OR = 1.16, 95% CI = 1.01--1.34, *P* \< 0.001, and allele comparison: OR = 1.13, 95% CI = 1.03--1.24, *P* \< 0.001), low-quality studies (allele comparison: OR = 1.12, 95% CI = 1.02--1.23, *P* \< 0.001) and high-quality studies (homozygous: OR = 1.08, 95% CI = 1.00--1.17, *P* = 0.001; heterozygous: OR = 1.07, 95% CI = 1.02--1.13, *P* = 0.067; dominant: OR = 1.07, 95% CI = 1.02--1.14, *P* = 0.002; and allele comparison: OR = 1.04, 95% CI = 1.00--1.09, *P* \< 0.001).

3.3. Heterogeneity and Sensitivity Analysis {#sec3.3}
-------------------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, substantial heterogeneities were found among all studies for the *MnSOD* Val16Ala polymorphism and overall cancer risk (homozygous: *P* \< 0.001; heterozygous: *P* = 0.001; recessive: *P* \< 0.001; dominant: *P* \< 0.001; and allele comparison: *P* \< 0.001). Therefore, the random-effects model was used to generate wider CIs. The leave-one-out sensitivity analysis indicated that no single study could change the pooled ORs obviously (data not shown).

3.4. Publication Bias {#sec3.4}
---------------------

Begg\'s funnel plot and Egger\'s test were performed to evaluate the publication bias of 88 studies, and we found significant publication bias for the homozygous model (*P* = 0.049), recessive model (*P* = 0.007), dominant model (*P* = 0.042), and allele comparison (*P* = 0.007), but not for the heterozygous model (*P* = 0.056). Therefore, the Duval and Tweedie nonparametric "trim and fill" method was used to adjust for publication bias. The "trim and fill" method did not draw different conclusions (data not shown), indicating that our findings were statistically robust.

3.5. False-Positive Report Probability (FPRP) Analysis {#sec3.5}
------------------------------------------------------

The FPRP values were calculated for all the significant findings ([Table 3](#tab3){ref-type="table"}). With the assumption of a prior probability of 0.1, the FPRP results revealed that three genetic models \[Val/Ala versus Val/Val, (Ala/Ala + Val/Ala) versus Val/Val, and Ala versus Val\] of the *MnSOD* Val16Ala polymorphism were truly associated with increased cancer risk (FPRP = 0.032, 0.045, and 0.106, resp.). In addition, according to the FPRP results, we confirmed that the *MnSOD* Val16Ala polymorphism was associated with cancer risk for prostate cancer (heterozygous: FPRP = 0.020 and dominant: FPRP = 0.006), Caucasians (heterozygous: FPRP = 0.008 and dominant: FPRP = 0.045), population-based studies (homozygous: FPRP = 0.136, heterozygous: FPRP = 0.032 and dominant: FPRP = 0.119), hospital-based studies (allele comparison: FPRP = 0.082), low-quality studies (allele comparison: FPRP = 0.138), and high-quality studies (heterozygous: FPRP = 0.119).

4. Discussion {#sec4}
=============

In this meta-analysis, we comprehensively assessed the association between *MnSOD* Val16Ala polymorphism and cancer risk through 88 studies, and we found that this gene polymorphism was significantly associated with overall cancer risk. Further, stratification analysis revealed that the association was more obvious for risk of prostate cancer, Asians, Caucasians, population-based studies, hospital-based studies, low-quality studies, and high-quality studies. To avoid the false-positive results of the meta-analysis, we performed the FPRP analysis for the significant findings by setting as the prior probability of 0.1, and the results suggested that the association between *MnSOD* Val16Ala polymorphism and cancer risk for Asians was false positive, which may due to limited sample size.

MnSOD is a mitochondrial enzyme that converts superoxide radical O~2~^−^ into H~2~O~2~, and it plays a critical role in human cells. Studies have revealed that the aberrant expression of MnSOD is involved in many types of cancers. Our current study indicated that the *MnSOD* Val16Ala polymorphism was significantly associated with an increased overall cancer risk. Previous meta-analyses have also assessed the association of *MnSOD* Val16Ala polymorphism with cancer susceptibility. The study carried out by Kang \[[@B130]\] analyzed *MnSOD* Val16Ala polymorphism and cancer risk, consisting 52 studies with 26,865 cases and 32,464 controls, in which no significant association was found between this polymorphism and overall cancer risk. In the subgroup analysis, statistically significant associations were found between this polymorphism and non-Hodgkin lymphoma, lung cancer, and colorectal cancer. Another meta-analysis \[[@B131]\] including 7366 cases and 9102 controls found no overall association of *MnSOD* Val16Ala polymorphism for cancer risk. Some of the significant associations detected in the previous meta-analyses were not found in the present study; for example, *MnSOD* Val16Ala polymorphism was associated with the risk of hepatocellular carcinoma \[[@B132], [@B133]\], esophageal cancer \[[@B134]\], and lung cancer \[[@B134]\]. The discrepancy that occurred may be because our current study was based on a much larger sample size, allowing the more precise detection of the association. In the subgroup analysis by cancer type, we found a significant association between *MnSOD* Val16Ala polymorphism and elevated prostate cancer risk, and no significant association between this polymorphism and breast cancer, which were consistent with previous meta-analyses \[[@B131], [@B134]--[@B137]\].

In spite of genetic importance, environment factors such as dietary pattern and exercise play important roles in the development of cancer. Recently, several studies have investigated the association between dietary intake of antioxidant-rich foods and *MnSOD* Val16Ala polymorphism in breast cancer \[[@B60]\], prostate cancer \[[@B60]\], and cervical cancer \[[@B14]\]. Despite the lack of consistent data, the results suggested that the *MnSOD* Val16Ala polymorphism and cancer risk could be modulated by dietary factors. Besides, a previous study had shown that moderate exercise training is beneficial for prostate cancer \[[@B138]\], and evidence showed that exercise training may result in positive MnSOD modulation through redox sensitive pathways \[[@B139]\].

The current meta-analysis has several advantages. First, we included the latest publications in the present study and also the publications written in Chinese. Second, the quality of included studies was assessed by the quality score criteria. Third, the FPRP test was performed to make the results more trustworthy and robust. Although the study is the largest and most comprehensive one regarding the association between *MnSOD* Val16Ala polymorphism and all cancer types, there were still some limitations that should be addressed. First, the number of cases in each study was small (\<1000) in all but seven studies \[[@B11], [@B38], [@B69], [@B78], [@B82], [@B86], [@B119]\], which may have an effect on the investigation of the real association. Second, the results were based on unadjusted estimates, which might make the results imprecise. Third, only publications in English and Chinese were included, which could lead to selection bias. Fourth, in the subgroup analysis by cancer type, less than three studies were included for some types of cancer, which may affect the detection of the real association. Finally, the potential gene-gene, and gene-environment interactions were not investigated due to the lack of original information.

Despite of these limitations, this meta-analysis indicated there was a significant association between *MnSOD* Val16Ala polymorphism and cancer risk, which should be further validated by single large studies.
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![Flowchart of included studies for the association between *MnSOD* Val16Ala polymorphism and cancer susceptibility.](DM2018-3061974.001){#fig1}

![Forest plot of overall cancer risk associated with *MnSOD* Val16Ala polymorphism by dominant model. For each study, the estimated of OR and its 95% CI are plotted with a box and a horizontal line. ◇, pooled ORs and its 95% CIs.](DM2018-3061974.002){#fig2}

###### 

Characteristics of studies included in the meta-analysis.

  Surname (ref)                                  Year   Country      Ethnicity   Cancer type       Control source   Genotype method     Case                      Control                  MAF   HWE                        Score                                                       
  ---------------------------------------------- ------ ------------ ----------- ----------------- ---------------- ------------------- ------------------------- ------------------------ ----- -------------------------- ------------------------ ------ ----- ------ ------ ------- ----
  Ambrosone et al. \[[@B60]\]                    1999   USA          Caucasian   Breast            PB               PCR-RFLP            16                        53                       45    114                        25                       62     23    110    0.49   0.181   12
  Mitrunen et al. \[[@B10]\]                     2001   Finland      Caucasian   Breast            PB               PCR-RFLP            124                       255                      100   479                        153                      231    98    482    0.44   0.526   13
  Wang et al. \[[@B7]\]                          2001   USA          Caucasian   Lung              HB               Pyrosequencing      305                       551                      245   1101                       288                      628    323   1239   0.49   0.609   9
  Green et al. \[[@B61]\]                        2002   UK           Caucasian   Breast            HB               PCR-RFLP            13                        17                       9     39                         8                        22     6     36     0.47   0.175   5
  Hirvonen et al. \[[@B62]\]                     2002   Finland      Caucasian   MPM               PB               PCR-RFLP            6                         11                       3     20                         15                       36     12    63     0.48   0.248   9
  Levine et al. \[[@B63]\]                       2002   USA          Mixed       CRC               PB               PCR-RFLP            139                       209                      108   456                        140                      234    121   495    0.48   0.237   12
  Li et al. \[[@B64]\]                           2002   USA          Caucasian   Pancreatic        PB               PCR-RFLP            10                        11                       3     24                         8                        10     5     23     0.43   0.580   6
  Stoehlmacher et al. \[[@B13]\]                 2002   USA          Caucasian   CRC               PB               TaqMan              25                        65                       35    125                        21                       64     37    122    0.43   0.456   5
  Egan et al. \[[@B16]\]                         2003   USA          Caucasian   Breast            PB               PCR-RFLP            102                       250                      118   470                        130                      240    127   497    0.50   0.446   10
  Lin et al. \[[@B65]\]^a^                       2003   China        Asian       Lung              HB               PCR-RFLP            139                       59 (Val/Ala + Ala/Ala)   198   233                        99 (Val/Ala + Ala/Ala)   332    NA    NA     10             
  Woodson et al. \[[@B66]\]                      2003   USA          Caucasian   Prostate          PB               MALDI-TOF MS        43                        98                       58    199                        49                       102    40    191    0.48   0.330   12
  Cai et al. \[[@B11]\]                          2004   China        Asian       Breast            PB               PCR-RFLP            831                       266                      28    1125                       884                      290    23    1197   0.14   0.890   15
  Hung et al. \[[@B8]\]                          2004   Italy        Caucasian   Bladder           HB               PCR-RFLP            68                        89                       44    201                        45                       115    54    214    0.48   0.262   9
  Ichimura et al. \[[@B67]\]                     2004   Japan        Asian       Bladder           HB               PCR-RFLP            169                       41                       3     213                        157                      48     4     209    0.13   0.882   11
  Knight et al. \[[@B68]\]                       2004   Canada       Caucasian   Breast            PB               PCR-SSCP            107                       187                      105   399                        90                       195    87    372    0.50   0.350   14
  Lan et al. \[[@B17]\]                          2004   China        Asian       Lung              PB               Real-time PCR       93                        23                       3     119                        81                       30     1     112    0.14   0.321   10
  Millikan et al. \[[@B69]\]                     2004   USA          African     Breast            PB               TaqMan              259                       372                      129   760                        196                      357    124   677    0.45   0.083   13
  Millikan et al. \[[@B69]\]                     2004   USA          Caucasian   Breast            PB               TaqMan              273                       681                      311   1265                       266                      586    283   1135   0.49   0.269   13
  Olson et al. \[[@B70]\]                        2004   USA          Caucasian   Ovarian           HB               MALDI-TOF MS        27                        64                       27    118                        51                       87     39    177    0.47   0.869   9
  Tamimi et al. \[[@B71]\]                       2004   USA          Caucasian   Breast            PB               Mixed^d^            255                       468                      245   968                        297                      612    296   1205   0.50   0.584   15
  Bergman et al. \[[@B9]\]                       2005   Sweden       Caucasian   Breast            PB               Sequencing          33                        73                       12    118                        43                       88     43    174    0.50   0.879   11
  Cheng et al. \[[@B72]\]                        2005   China        Asian       Breast            HB               MassARRAY           343                       115                      11    469                        545                      183    11    739    0.14   0.322   11
  Gaudet et al. \[[@B38]\]                       2005   USA          Caucasian   Breast            PB               MALDI-TOF MS        253                       511                      270   1034                       264                      539    281   1084   0.49   0.862   14
  Landi et al. \[[@B73]\]                        2005   Spain        Caucasian   CRC               HB               APEX                94                        164                      77    335                        88                       151    64    303    0.46   0.958   5
  Li et al. \[[@B74]\]                           2005   USA          Caucasian   Prostate          PB               PCR-RFLP            132                       288                      147   567                        190                      379    195   764    0.50   0.829   14
  Terry et al. \[[@B75]\]                        2005   USA          Caucasian   Bladder           HB               MALDI-TOF MS        54                        122                      59    235                        57                       103    54    214    0.49   0.586   8
  Ho et al. \[[@B18]\]^c^                        2006   China        Asian       Lung              HB               PCR-RFLP            176                       58                       0     234                        180                      52     7     239    0.14   0.184   7
  Lightfoot et al. \[[@B76]\]                    2006   USA and UK   Caucasian   NHL               PB               TaqMan              211                       463                      229   903                        358                      713    371   1442   0.50   0.676   13
  Slanger et al. \[[@B77]\]                      2006   Germany      Caucasian   Breast            PB               TaqMan              144                       318                      152   614                        263                      528    289   1080   0.49   0.477   14
  Wang et al. \[[@B78]\]                         2006   USA          Mixed       NHL               PB               TaqMan              285                       545                      290   1120                       240                      486    211   937    0.48   0.240   13
  Cengiz et al. \[[@B15]\]^b^                    2007   Turkey       Caucasian   Bladder           HB               PCR-RFLP            34 (Val/Val + Val/Ala)    17                       51    34 (Val/Val + Val/Ala)     19                       53     NA    NA     7              
  Choi et al. \[[@B37]\]                         2007   USA          Caucasian   Prostate          PB               MALDI-TOF MS        112                       239                      104   455                        293                      610    311   1214   0.49   0.857   13
  Choi et al. \[[@B37]\]                         2007   USA          African     Prostate          PB               MALDI-TOF MS        7                         15                       6     28                         39                       52     31    122    0.47   0.112   10
  Ergen et al. \[[@B79]\]^c^                     2007   Turkey       Caucasian   Prostate          HB               PCR-RFLP            19                        25                       6     50                         32                       18     0     50     0.18   0.121   7
  Han et al. \[[@B80]\]                          2007   USA          Caucasian   Skin              PB               TaqMan              184                       402                      187   773                        196                      425    212   833    0.49   0.549   15
  Johnatty et al. \[[@B81]\]                     2007   Australia    Caucasian   Ovarian           PB               Real-time PCR       123                       273                      147   543                        276                      546    308   1130   0.49   0.269   11
  Kang et al. \[[@B82]\]                         2007   USA          Caucasian   Prostate          PB               TaqMan              275                       578                      297   1150                       376                      686    320   1382   0.48   0.835   13
  Kang et al. \[[@B82]\]                         2007   USA          African     Prostate          PB               TaqMan              31                        57                       15    103                        122                      194    79    395    0.45   0.906   11
  Landi et al. \[[@B83]\]                        2007   Italy        Caucasian   MPM               HB               APEX                16                        27                       37    80                         98                       170    81    349    0.48   0.661   9
  di Martino et al. \[[@B84]\]                   2007   USA          Caucasian   Esophageal        HB               PCR-RFLP            32                        73                       35    140                        20                       39     34    93     0.42   0.171   8
  Murphy et al. \[[@B12]\]                       2007   Ireland      Caucasian   Esophageal        PB               SNaPshot            44                        103                      60    207                        60                       113    48    221    0.47   0.703   11
  Arsova-Sarafinovska et al. \[[@B85]\]          2008   Turkey       Caucasian   Prostate          HB               Real-time PCR       19                        46                       20    85                         41                       73     37    151    0.49   0.690   9
  Cooper et al. \[[@B86]\]                       2008   USA          Caucasian   Prostate          PB               TaqMan              602                       1352                     680   2634                       423                      789    424   1636   0.50   0.152   15
  Dalan et al. \[[@B87]\]                        2008   Turkey       Caucasian   Ovarian           PB               PCR-RFLP            30                        19                       6     55                         28                       17     6     51     0.28   0.196   7
  Justenhoven et al. \[[@B88]\]                  2008   Germany      Caucasian   Breast            PB               MALDI-TOF MS        159                       312                      133   604                        163                      313    145   621    0.49   0.824   14
  Mikhak et al. \[[@B89]\]                       2008   USA          Caucasian   Prostate          PB               TaqMan              156                       320                      166   642                        162                      331    159   652    0.50   0.695   14
  Rajaraman et al. \[[@B90]\]                    2008   USA          Caucasian   Brain             HB               TaqMan              129                       262                      123   514                        122                      220    109   451    0.49   0.617   10
  Wheatley-Price et al. \[[@B91]\]               2008   USA          Caucasian   Pancreatic        HB               TaqMan              33                        58                       31    122                        61                       165    105   331    0.43   0.786   11
  Zienolddiny et al. \[[@B92]\]                  2008   Norway       Caucasian   Lung              PB               APEX                74                        175                      70    319                        119                      178    78    375    0.45   0.448   12
  Eras-Erdogan et al. \[[@B93]\]                 2009   Turkey       Caucasian   Breast            PB               PCR-RFLP            107                       113                      30    250                        150                      141    39    330    0.33   0.508   8
  Funke et al. \[[@B94]\]                        2009   Germany      Caucasian   CRC               PB               Pyrosequencing      136                       321                      166   623                        146                      294    163   603    0.49   0.554   12
  Iguchi et al. \[[@B95]\]                       2009   USA          Mixed       Prostate          HB               PCR-RFLP            41                        86                       60    187                        40                       96     39    175    0.50   0.199   6
  Kostrykina et al. \[[@B96]\]                   2009   Russia       Caucasian   Breast            PB               TaqMan              123                       233                      119   475                        103                      183    90    376    0.48   0.622   12
  Tong et al. \[[@B14]\]^a^                      2009   Korea        Asian       Cervical          HB               SNaPshot            72                        27 (Val/Ala + Ala/Ala)   99    194                        69 (Val/Ala + Ala/Ala)   263    NA    NA     7              
  Ermolenko et al. \[[@B97]\]                    2010   Russia       Caucasian   Breast            HB               Real-time PCR       228                       454                      239   921                        121                      235    104   460    0.48   0.620   9
  Ezzikouri et al. \[[@B98]\]                    2010   Morocco      Caucasian   HCC               PB               PCR-RFLP            21                        45                       30    96                         81                       101    40    222    0.41   0.388   11
  Ibrahim et al. \[[@B99]\]                      2010   Egypt        African     HCC               HB               PCR-RFLP            16                        32                       27    75                         19                       28     11    58     0.43   0.904   8
  Kim et al. \[[@B100]\]                         2010   Korea        Asian       Breast            HB               TaqMan              234                       66                       4     304                        279                      90     7     376    0.14   0.934   11
  Méplan et al. \[[@B101]\]                      2010   Czech        Caucasian   CRC               HB               AS-PCR              172                       358                      189   719                        165                      318    174   657    0.49   0.415   9
  Tang et al. \[[@B102]\]                        2010   USA          Mixed       Pancreatic        HB               TaqMan              143                       278                      137   558                        167                      309    162   638    0.50   0.429   11
  Wu et al. \[[@B103]\]                          2010   China        Asian       Oral              HB               Real-time PCR       91                        28                       2     121                        88                       32     2     122    0.15   0.637   9
  Yi et al. \[[@B104]\]                          2010   China        Asian       Gastric           HB               SNaPshot            85                        48                       7     140                        119                      27     1     147    0.10   0.690   9
  Cerne et al. \[[@B105]\]                       2011   Slovenia     Caucasian   Breast            HB               TaqMan              118                       269                      143   530                        65                       134    71    270    0.51   0.910   8
  Cheng et al. \[[@B106]\]^b^                    2011   USA          Mixed       Prostate          PB               MALDI-TOF MS        152 (Val/Val + Val/Ala)   50                       202   1054 (Val/Val + Val/Ala)   374                      1428   NA    NA     13             
  Mohelnikova-Duchonova et al. \[[@B107]\]       2011   Czech        Caucasian   Pancreatic        PB               Real-time PCR       66                        121                      48    235                        73                       134    58    265    0.47   0.812   10
  Zhang et al. \[[@B108]\]^b^                    2011   USA          Mixed       Pancreatic        PB               TaqMan              129 (Val/Val + Val/Ala)   60                       189   365 (Val/Val + Val/Ala)    121                      486    NA    NA     13             
  Atoum et al. \[[@B109]\]^c^                    2012   Jordan       Caucasian   Breast            HB               PCR-RFLP            22                        43                       0     65                         11                       6      0     17     0.18   0.377   6
  Farawela et al. \[[@B110]\]                    2012   Egypt        African     NHL               PB               PCR-RFLP            10                        50                       40    100                        12                       49     39    100    0.37   0.568   9
  Hemelrijck et al. \[[@B111]\]                  2012   Germany      Caucasian   Prostate          PB               MassARRAY           50                        100                      53    203                        80                       190    90    360    0.49   0.285   13
  Kucukgergin et al. \[[@B112]\]                 2012   Turkey       Caucasian   Bladder           HB               PCR-RFLP            52                        68                       37    157                        89                       99     36    224    0.38   0.341   8
  Kucukgergin et al. \[[@B113]\]                 2012   Turkey       Caucasian   Prostate          HB               PCR-RFLP            43                        65                       26    134                        66                       69     24    159    0.37   0.398   8
  Tsai et al. \[[@B114]\]^a^                     2012   China        Asian       Breast            HB               Real-time PCR       192                       68 (Val/Ala + Ala/Ala)   260   138                        86 (Val/Ala + Ala/Ala)   224    NA    NA     8              
  Ye et al. \[[@B115]\]                          2012   China        Asian       NPC               HB               PCR                 88                        15                       2     105                        110                      23     3     136    0.11   0.191   8
  Zhao et al. \[[@B116]\]                        2012   China        Asian       Brain             HB               OpenArray           241                       107                      31    379                        293                      81     6     380    0.12   0.882   11
  Amr et al. \[[@B117]\]                         2013   Egypt        African     Bladder           PB               TaqMan              127                       188                      99    414                        109                      160    87    356    0.47   0.065   13
  Ashour et al. \[[@B118]\]                      2013   Egypt        African     Lung              PB               TaqMan              17                        27                       6     50                         21                       25     4     50     0.33   0.355   9
  Attatippaholkun and Wikainapakul \[[@B119]\]   2013   Thailand     Asian       Cervical          HB               SNaPshot            64                        39                       4     107                        84                       48     3     135    0.20   0.184   7
  Attatippaholkun et al. \[[@B119]\]             2013   Thailand     Asian       Breast            HB               SNaPshot            82                        54                       5     141                        84                       48     3     135    0.20   0.184   7
  Eken et al. \[[@B120]\]                        2013   Turkey       Caucasian   Prostate          HB               Real-time PCR       7                         17                       9     33                         31                       37     13    81     0.39   0.726   8
  Han et al. \[[@B121]\]                         2013   Korea        Asian       Pancreatic        PB               PCR-SSCP            190                       85                       19    294                        236                      59     5     300    0.12   0.558   12
  Méplan et al. \[[@B122]\]                      2013   Denmark      Caucasian   Breast            PB               TaqMan              228                       485                      226   939                        237                      494    227   958    0.49   0.331   14
  Atilgan et al. \[[@B123]\]                     2014   Turkey       Caucasian   RCC               HB               Probe               10                        17                       14    41                         23                       19     8     50     0.35   0.244   5
  Liu et al \[[@B124]\]                          2014   China        Asian       OSCC              HB               PCR-RFLP            272                       83                       7     362                        296                      61     1     358    0.09   0.243   10
  Oskina et al. \[[@B125]\]                      2014   Russia       Caucasian   Prostate          PB               TaqMan              92                        194                      94    380                        86                       152    99    337    0.48   0.076   12
  Brown et al. \[[@B126]\]                       2015   USA          Mixed       Medulloblastoma   PB               Illumina SNP chip   3                         15                       8     26                         18                       18     9     45     0.40   0.264   5
  Jablonska et al. \[[@B127]\]                   2015   Polish       Caucasian   Breast            PB               Real-time PCR       32                        75                       29    136                        41                       92     50    183    0.48   0.915   10
  Parlaktas et al. \[[@B128]\]                   2015   Turkey       Caucasian   Prostate          HB               Probe               23                        23                       3     49                         24                       20     5     49     0.31   0.784   7
  Su et al. \[[@B129]\]                          2015   China        Asian       HCC               HB               PCR-RFLP            334                       78                       10    422                        359                      107    13    479    0.14   0.150   7

MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium; HB: hospital-based; PB: population based; NA, not applicable; PCR-RFLP: polymorphism chain reaction-restriction fragment length polymorphism; MALDI-TOF MS: matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry; PCR-SSCP: polymorphism chain reaction-single strand conformation polymorphism; APEX: arrayed primer extension; AS-PCR: allele specific-polymorphism chain reaction; MPM: malignant pleural mesothelioma; CRC: colorectal cancer; NHL: non-Hodgkin\'s lymphoma; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; OSCC: oral squamous cell carcinoma. ^a^Lin et al. \[[@B65]\], Tong et al. \[[@B14]\], and Tsai et al. \[[@B114]\] were only calculated for the dominant model. ^b^Cengiz et al. \[[@B15]\], Cheng et al. \[[@B106]\], and Zhang et al. \[[@B108]\] were only calculated for the recessive model. ^c^Ho et al. \[[@B18]\], Ergen et al. \[[@B79]\], and Atoum et al. \[[@B109]\] were only calculated for the heterozygous model, dominant model, and allele comparison, and the number of Ala/Ala genotype was zero. ^d^Mixed: which included more than one genotyping methods.

###### 

Meta-analysis of the association between *MnSOD* Val16Ala polymorphism and cancer risk.

  Variables           Number of studies   Sample size (case/controls)   Homozygous              Heterozygous   Recessive               Dominant   Allele comparison                                                                           
  ------------------- ------------------- ----------------------------- ----------------------- -------------- ----------------------- ---------- ----------------------- --------- ----------------------- --------- ----------------------- ---------
  All                 88                  33,098/37,831                 **1.09 (1.00--1.19)**   \<0.001        **1.07 (1.02--1.12)**   0.001      1.05 (0.99--1.11)       \<0.001   **1.08 (1.02--1.14)**   \<0.001   **1.06 (1.02--1.11)**   \<0.001
  Cancer type                                                                                                                                                                                                                                 
  Breast              24                  12,479/12,603                 1.03 (0.95--1.13)       0.276          1.02 (0.96--1.09)       0.302      1.02 (0.94--1.10)       0.157     1.01 (0.94--1.09)       0.066     1.02 (0.97--1.06)       0.226
  Prostate            17                  7101/9146                     1.04 (0.87--1.24)       0.002          **1.14 (1.05--1.24)**   0.765      1.03 (0.94--1.14)       0.225     **1.14 (1.05--1.23)**   0.552     **1.07 (1.00--1.15)**   0.106
  Lung                6                   2021/2347                     1.13 (0.63--2.04)       0.019          1.05 (0.76--1.46)       0.016      0.91 (0.72--1.14)       0.313     1.02 (0.78--1.32)       0.021     0.98 (0.80--1.21)       0.039
  Bladder             6                   1271/1270                     0.66 (0.39--1.13)       0.002          0.91 (0.68--1.23)       0.049      1.01 (0.83--1.24)       0.520     0.93 (0.68--1.26)       0.021     0.97 (0.80--1.19)       0.033
  Pancreatic          6                   1422/2043                     1.01 (0.59--1.73)       0.007          1.07 (0.77--1.49)       0.032      1.08 (0.77--1.50)       0.020     1.04 (0.70--1.55)       0.002     1.04 (0.76--1.43)       \<0.001
  CRC                 5                   2258/2180                     1.02 (0.86--1.20)       0.856          1.04 (0.90--1.20)       0.733      0.99 (0.86--1.13)       0.967     1.03 (0.90--1.18)       0.733     1.01 (0.93--1.09)       0.863
  Ovarian             3                   716,1358                      1.10 (0.85--1.42)       0.839          1.15 (0.92--1.45)       0.773      1.00 (0.81--1.23)       0.973     1.13 (0.92--1.40)       0.748     1.05 (0.92--1.19)       0.836
  HCC                 3                   593/759                       1.92 (0.85--4.36)       0.050          1.15 (0.66--2.00)       0.055      1.70 (0.97--2.97)       0.162     1.36 (0.67--2.76)       0.005     1.34 (0.76--2.35)       0.001
  NHL                 3                   2123/2479                     1.96 (0.96--4.00)       \<0.001        1.03 (0.89--1.19)       0.551      1.08 (0.94--1.24)       0.357     1.05 (0.92--1.20)       0.831     1.05 (0.96--1.14)       0.849
  Other cancers       15                  3114/3646                     1.79 (1.18--2.70)       \<0.001        1.25 (1.05--1.49)       0.058      1.54 (1.07--2.20)       \<0.001   1.32 (1.08--1.61)       0.001     1.32 (1.08--1.61)       \<0.001
  Ethnicity                                                                                                                                                                                                                                   
  Asian               18                  5092/5748                     **1.82 (1.15--2.88)**   0.020          1.10 (0.94--1.30)       0.001      **1.76 (1.16--2.68)**   0.065     1.08 (0.91--1.29)       \<0.001   1.16 (0.96--1.40)       \<0.001
  Caucasian           56                  23,738/26,121                 1.03 (0.94--1.12)       \<0.001        **1.08 (1.03--1.13)**   0.208      1.02 (0.96--1.08)       0.005     **1.08 (1.02--1.14)**   0.011     **1.04 (1.00--1.09)**   \<0.001
  African             7                   1530/1758                     1.58 (0.85--2.93)       \<0.001        0.95 (0.80--1.12)       0.442      0.98 (0.79--1.21)       0.314     0.99 (0.81--1.20)       0.289     1.01 (0.87--1.17)       0.168
  Mixed               7                   2738/4204                     1.11 (0.88--1.42)       0.141          0.98 (0.81--1.19)       0.196      1.12 (0.97--1.31)       0.187     1.02 (0.85--1.23)       0.177     1.06 (0.94--1.21)       0.107
  Source of control                                                                                                                                                                                                                           
  PB                  48                  23,004/27,193                 **1.10 (1.01--1.19)**   \<0.001        **1.07 (1.02--1.12)**   0.263      1.02 (0.97--1.08)       0.071     **1.07 (1.02--1.13)**   0.071     **1.04 (1.00--1.08)**   0.006
  HB                  40                  10,094/10,638                 1.09 (0.88--1.35)       \<0.001        1.08 (0.98--1.20)       0.003      **1.16 (1.01--1.34)**   \<0.001   1.10 (0.98--1.23)       \<0.001   **1.13 (1.03--1.24)**   \<0.001
  Quality score                                                                                                                                                                                                                               
  Low                 39                  7625/7608                     1.15 (0.90--1.46)       \<0.001        1.09 (0.98--1.22)       0.025      1.13 (0.99--1.29)       0.015     1.11 (0.98--1.26)       \<0.001   **1.12 (1.02--1.23)**   \<0.001
  High                49                  25,473/30,223                 **1.08 (1.00--1.17)**   0.001          **1.07 (1.02--1.13)**   0.067      1.03 (0.97--1.09)       0.002     **1.07 (1.02--1.14)**   0.002     **1.04 (1.00--1.09)**   \<0.001

Het: heterogeneity; CRC: colorectal cancer; HCC: hepatocellular carcinoma; NHL: non-Hodgkin\'s lymphoma; PB: population-based; HB: hospital-based.

###### 

False-positive report probability values for associations between cancer risk and *MnSOD* Val16Ala polymorphism.

  Genotype                        Crude OR (95% CI)   *P* value^a^   Statistical power^b^   Prior probability                                   
  ------------------------------- ------------------- -------------- ---------------------- ------------------- ----------- ----------- ------- -------
  All                                                                                                                                           
  Homozygous                      1.09 (1.00--1.19)   0.054          1.000                  **0.140**           0.328       0.843       0.982   0.998
  Heterozygous                    1.07 (1.02--1.12)   0.004          1.000                  **0.011**           **0.032**   0.267       0.787   0.974
  Dominant                        1.08 (1.02--1.14)   0.005          1.000                  **0.016**           **0.045**   0.343       0.840   0.981
  Allele comparison               1.06 (1.02--1.11)   0.013          1.000                  **0.038**           **0.106**   0.567       0.930   0.992
  Cancer type---prostate cancer                                                                                                                 
  Heterozygous                    1.14 (1.05--1.24)   0.002          1.000                  **0.007**           **0.020**   **0.183**   0.693   0.958
  Dominant                        1.14 (1.05--1.23)   0.001          1.000                  **0.002**           **0.006**   **0.067**   0.420   0.879
  Allele comparison               1.07 (1.00--1.15)   0.066          1.000                  **0.165**           0.372       0.867       0.985   0.998
  Ethnicity---Asian                                                                                                                             
  Homozygous                      1.82 (1.15--2.88)   0.011          0.204                  **0.134**           0.317       0.836       0.981   0.998
  Recessive                       1.76 (1.16--2.68)   0.008          0.228                  **0.100**           0.249       0.785       0.974   0.997
  Ethnicity--Caucasian                                                                                                                          
  Heterozygous                    1.08 (1.03--1.13)   0.001          1.000                  **0.003**           **0.008**   **0.078**   0.462   0.896
  Dominant                        1.08 (1.02--1.14)   0.005          1.000                  **0.016**           **0.045**   0.343       0.840   0.981
  Allele comparison               1.04 (1.00--1.09)   0.102          1.000                  0.234               0.478       0.910       0.990   0.999
  Control source---PB                                                                                                                           
  Homozygous                      1.10 (1.01--1.19)   0.018          1.000                  **0.050**           **0.136**   0.634       0.946   0.994
  Heterozygous                    1.07 (1.02--1.12)   0.004          1.000                  **0.011**           **0.032**   0.267       0.787   0.974
  Dominant                        1.07 (1.02--1.13)   0.015          1.000                  **0.043**           **0.119**   0.599       0.938   0.993
  Allele comparison               1.04 (1.00--1.08)   0.042          1.000                  **0.111**           0.273       0.805       0.977   0.998
  Control source---HB                                                                                                                           
  Recessive                       1.16 (1.01--1.34)   0.044          1.000                  **0.116**           0.282       0.812       0.978   0.998
  Allele comparison               1.13 (1.03--1.24)   0.010          1.000                  **0.029**           **0.082**   0.495       0.908   0.990
  Quality score---low                                                                                                                           
  Allele comparison               1.12 (1.02--1.23)   0.018          1.000                  **0.051**           **0.138**   0.637       0.947   0.994
  Quality score---high                                                                                                                          
  Homozygous                      1.08 (1.00--1.17)   0.059          1.000                  **0.151**           0.349       0.855       0.983   0.998
  Heterozygous                    1.07 (1.02--1.13)   0.015          1.000                  **0.043**           **0.119**   0.599       0.938   0.993
  Dominant                        1.07 (1.02--1.14)   0.036          1.000                  **0.098**           0.247       0.783       0.973   0.997
  Allele comparison               1.04 (1.00--1.09)   0.102          1.000                  0.234               0.478       0.910       0.990   0.999

^a^Chi-square test was used to calculate the genotype frequency distributions; ^b^statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

[^1]: Academic Editor: Roberta Rizzo
